Research programme: HMG CoA reductase inhibitors - Tel Aviv University

Drug Profile

Research programme: HMG CoA reductase inhibitors - Tel Aviv University

Alternative Names: HMG CoA reductase inhibitors research programme - Tel Aviv University

Latest Information Update: 18 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ramot at Tel Aviv University; Tel Aviv University
  • Class
  • Mechanism of Action HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Skin disorders

Most Recent Events

  • 20 Dec 2005 No development reported - Clinical-Phase-Unknown for Skin disorders in Israel (unspecified route)
  • 04 Apr 2001 This programme is available for licensing (
  • 04 Apr 2001 Investigation in Skin disorders in Israel (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top